Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics.
Organic anion transporter (OAT) genes have been implicated in renal secretion of organic anions, but the individual in vivo contributions of OAT1 (first identified as NKT) and OAT3 remain unclear. Potential substrates include loop diuretics (e.g., furosemide) and thiazide diuretics (e.g., bendroflumethiazide), which reach their tubular sites of action mainly by proximal tubular secretion. Previous experiments in Oat1 knockout (-/-) mice revealed an almost complete loss of renal secretion of the prototypic organic anion p-aminohippurate (PAH) and a role of OAT1 in tubular secretion of furosemide (Eraly SA, Vallon V, Vaughn D, Gangoiti JA, Richter K, Nagle M, Monte JC, Rieg T, Truong DM, Long JM, Barshop BA, Kaler G, Nigam SK. J Biol Chem 281: 5072-5083, 2006). In this study we found that both furosemide and bendroflumethiazide inhibited mOat1- and mOat3-mediated uptake of a labeled tracer in Xenopus oocytes injected with cRNA, consistent with their being substrates for mouse OAT1 and OAT3. Experiments in Oat3(-/-) mice revealed intact renal secretion of PAH, but the dose-natriuresis curves for furosemide and bendroflumethiazide were shifted to the right and urinary furosemide excretion was impaired similar to the defect in Oat1(-/-) mice. Thus, whereas OAT1 (in contrast to OAT3) is the classic basolateral PAH transporter of the proximal tubule, both OAT1 and OAT3 contribute similarly to normal renal secretion of furosemide and bendroflumethiazide, and a lack of either one is not fully compensated by the other. Although microarray expression analysis in the kidneys of Oat1(-/-) and Oat3(-/-) mice revealed somewhat altered expression of a small number of transport-related genes, none were common to both knockout models. When searching for polymorphisms involved in human diuretic responsiveness, it may be necessary to consider both OAT1 and OAT3, among other genes.
Vallon
Volker
V
Dept. of Medicine, Univ. of California, San Diego and VASDHCS, 3350 La Jolla Village Drive (9151) San Diego, CA 92161, USA. vvallon@ucsd.edu
Rieg
Timo
T
Ahn
Sun Young
SY
Wu
Wei
W
Eraly
Satish A
SA
Nigam
Sanjay K
SK
D000818:Animals; D001539:Bendroflumethiazide / Q000494:pharmacology; D004232:Diuretics / Q000494:pharmacology; D005260:Female; D005665:Furosemide / Q000494:pharmacology; D007328:Insulin / Q000494:pharmacology; D009865:Oocytes / Q000187:drug effects / Q000502:physiology*; D027362:Organic Anion Transport Protein 1 / Q000187:drug effects / Q000502:physiology*; D029362:Organic Anion Transporters, Sodium-Independent / Q000187:drug effects / Q000502:physiology*; D049993:Sodium Chloride Symporter Inhibitors / Q000494:pharmacology*; D049994:Sodium Potassium Chloride Symporter Inhibitors / Q000494:pharmacology*; D014981:Xenopus; D010130:p-Aminohippuric Acid / Q000494:pharmacology
D004232:Diuretics; D007328:Insulin; D027362:Organic Anion Transport Protein 1; D029362:Organic Anion Transporters, Sodium-Independent; D049993:Sodium Chloride Symporter Inhibitors; D049994:Sodium Potassium Chloride Symporter Inhibitors; C114338:organic anion transport protein 3; D001539:Bendroflumethiazide; D005665:Furosemide; D010130:p-Aminohippuric Acid